Study wrapper · #591
Hexarelin protects cardiac H9C2 cells from angiotensin II-induced hypertrophy via the regulation of autophagy.
Editor's note
This is an in-vitro study in H9C2 rat cardiomyocytes made hypertrophic with angiotensin-II. Researchers reported that hexarelin, a synthetic growth hormone-releasing peptide, reduced cell enlargement, oxidative stress, and cell death while enhancing autophagy, and that blocking autophagy abolished these benefits. The proposed mechanism involves suppression of mTOR signaling. It is a coherent mechanistic account that fits hexarelin's broader cardioprotective narrative, but it rests entirely on a cell line exposed to a single hypertrophic stimulus. Cell-line results do not capture the intact heart, and pathway conclusions drawn from pharmacological inhibitors warrant caution. These are preclinical findings; human data are needed before any clinical conclusions can be drawn.
Plain-language abstract
Using rat heart-muscle cells grown in the lab and made to enlarge (a stand-in for the harmful heart growth seen in disease) with angiotensin-II, scientists tested hexarelin, a synthetic peptide. Hexarelin reduced the cells' enlargement, oxidative stress, and death, and improved their survival. It did this in part by boosting autophagy, the cell's internal recycling and cleanup process; when the researchers blocked autophagy, hexarelin's benefits disappeared. They also found hexarelin acted through a signaling molecule called mTOR. The authors conclude hexarelin counters harmful heart-cell enlargement through an autophagy-dependent mechanism. This is a preclinical study in isolated cells, not animals or people; human research would be needed before drawing clinical conclusions.